VVUS - VIVUS, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.82
-0.28 (-6.83%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.10
Open4.11
Bid3.37 x 1200
Ask4.25 x 800
Day's Range3.82 - 4.17
52 Week Range3.30 - 9.90
Volume73,958
Avg. Volume74,107
Market Cap40.694M
Beta (3Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-3.72
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • GlobeNewswire12 days ago

    VIVUS to Present at the BIO Investor Forum on October 17, 2018

    CAMPBELL, Calif., Oct. 10, 2018 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of.

  • GlobeNewswire26 days ago

    VIVUS Regains Compliance with Nasdaq Listing Requirements

    VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today that it has regained full compliance with Nasdaq listing requirements. In a letter dated September 25, 2018, Nasdaq informed the Company that it has achieved compliance with the minimum bid price rule and is in compliance with other applicable requirements required for continued listing on The Nasdaq Capital Market. “When we assembled the new management team in April, combining three new officers with the existing VIVUS team, we articulated a set of key priorities.

  • GlobeNewswire28 days ago

    VIVUS to Present at the Fourth Annual Robins Equity Research Round-Up

    CAMPBELL, Calif., Sept. 24, 2018-- VIVUS, Inc.,, a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today ...

  • GlobeNewswirelast month

    VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation’s CF Climb

    VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, announced today that it is supporting the Dallas-Fort Worth chapter of the Cystic Fibrosis Foundation (CFF) in its CF Climb fundraising event. This sponsorship demonstrates VIVUS’ support of the cystic fibrosis (CF) patient community as the Company launches PANCREAZE® (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI), a common complication of CF.

  • MarketWatchlast month

    Vivus stock rallies above $5 mark in volatile trade after reverse stock split takes effect

    Shares of Vivus Inc. rallied 6.6% to trade above the $5 mark in volatile morning trade Tuesday, after the biopharmaceutical company's 1-for-10 reverse stock split went into effect. The stock has been down as much as 12% at a split-adjusted intraday low of $4.15 and up as much as 18% at a high of $5.58 since the open. The stock had closed Monday at 47 cents on a pre-split basis. Vivus Chief Executive John Amos had said it enacted the split because it determined it would position the company with the "appropriate liquidity associated with listing shares on a major U.S. exchange," which Amos said was "critical" for the execution of its strategic plan to return to profitability. One of the Nasdaq's requirements for continued listing is a minimum bid price of $1 for a company's stock. Vivus shares have tumbled 43% over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 6.4% and the S&P 500 has tacked on 3.4%.

  • ACCESSWIRElast month

    New Growth Opportunities Jump for 3 Biotech Stocks in 2018

    CORAL GABLES, FL / ACCESSWIRE / September 11, 2018 / Biotech stocks continue to present key drivers of returns for many investors. Public equities have delivered strong returns underpinned by large-scale of monetary policy support. It is particularly noteworthy that the California Public Employees' Retirement System is considering the creation of a direct investment program, which would include investment in companies within sectors like healthcare and biotechnology.

  • GlobeNewswirelast month

    VIVUS Announces 1-for-10 Reverse Stock Split

    VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, announced today that the Company’s stockholders approved a reverse stock split. Effective September 10, 2018, the Company will enact a 1-for-10 reverse stock split of its common stock with shares trading on a split-adjusted basis on September 11, 2018. “The 1-for-10 ratio was determined following an analysis of over 700 companies that effected a reverse split from 1998 to 2018.

  • Why Is Vivus (VVUS) Down 6.4% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Vivus (VVUS) Down 6.4% Since Last Earnings Report?

    Vivus (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire2 months ago

    VIVUS Reports Data Supporting the Cardiovascular Safety of Qsymia®

    -Retrospective analysis presented at the 34 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management-. CAMPBELL, Calif., Aug. 27, 2018-- VIVUS, Inc., a biopharmaceutical company, ...

  • VIVUS' (VVUS) Qsymia Falters in a Highly Competitive Market
    Zacks2 months ago

    VIVUS' (VVUS) Qsymia Falters in a Highly Competitive Market

    VIVUS' (VVUS) Qsymia sales lackluster due to slow uptake of the drug and a competitive market.

  • GlobeNewswire2 months ago

    VIVUS to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 5, 2018

    CAMPBELL, Calif., Aug. 22, 2018-- VIVUS, Inc., a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of VVUS earnings conference call or presentation 7-Aug-18 8:30pm GMT

    Q2 2018 Vivus Inc Earnings Call

  • A Look at Novo Nordisk’s Human Insulin and Obesity Business
    Market Realist2 months ago

    A Look at Novo Nordisk’s Human Insulin and Obesity Business

    In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.

  • VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y
    Zacks2 months ago

    VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y

    VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.

  • Associated Press2 months ago

    Vivus: 2Q Earnings Snapshot

    The Campbell, California-based company said it had a loss of 12 cents per share. The biopharmaceutical company posted revenue of $15 million in the period. In the final minutes of trading on Tuesday, the ...

  • GlobeNewswire2 months ago

    VIVUS Reports Second Quarter 2018 Financial Results

    Company to host conference call today at 4:30pm ET. CAMPBELL, Calif., Aug. 07, 2018-- VIVUS, Inc., a specialty pharmaceutical company committed to the development and commercialization of innovative therapies ...

  • ACCESSWIRE2 months ago

    VIVUS, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / VIVUS, Inc. (NASDAQ: VVUS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To listen ...

  • GlobeNewswire3 months ago

    VIVUS Appoints Kenneth Suh as President

    CAMPBELL, Calif., Aug. 06, 2018-- VIVUS, Inc., a biopharmaceutical company, today announced the appointment of Ken Suh to the position of President. Suh was President and CEO of Willow Biopharma Inc., ...

  • GlobeNewswire3 months ago

    VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 7, 2018

    CAMPBELL, Calif., July 31, 2018-- VIVUS, Inc. today announced that it will report financial results and provide a business update for the second quarter of 2018 after the market close on Tuesday, August ...

  • VIVUS' PAH Candidate Data Positive in Early Stage Study
    Zacks3 months ago

    VIVUS' PAH Candidate Data Positive in Early Stage Study

    VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.

  • VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session
    Zacks3 months ago

    VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session

    VIVUS (VVUS) was a big mover last session, as the company saw its shares rise more than 10% on the day, amid huge volumes.

  • 3 Biotech Stocks Up in the Past Month on Industry Turnaround
    InvestorPlace4 months ago

    3 Biotech Stocks Up in the Past Month on Industry Turnaround

    After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! NANO DIMENSION/S ADR (NASDAQ: NNDM ) stock was trading ...

  • Can The Uptrend Continue for VIVUS (VVUS)?
    Zacks4 months ago

    Can The Uptrend Continue for VIVUS (VVUS)?

    Investors certainly have to be happy with VIVUS, Inc. (VVUS) and its short term performance